Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption

Rentian Feng, Qin Tong, Zhaojun Xie, Haizi Cheng, Lirong Wang, Suzanne Lentzsch, G. David Roodman, Xiang Qun Xie

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cannabinoid receptor-2 (CB2) is expressed dominantly in the immune system, especially on plasma cells. Cannabinergic ligands with CB2 selectivity emerge as a class of promising agents to treat CB2-expressing malignancies without psychotropic concerns. In this study, we found that CB2 but not CB1 was highly expressed in human multiple myeloma (MM) and primary CD138+ cells. A novel inverse agonist of CB2, phenylacetylamide but not CB1 inverse agonist SR141716, inhibited the proliferation of human MM cells (IC50: 0.62∼2.5μM) mediated by apoptosis induction, but exhibited minor cytotoxic effects on human normal mononuclear cells. CB2 gene silencing or pharmacological antagonism markedly attenuated phenylacetylamide's anti-MM effects. Phenylacetylamide triggered the expression of C/EBP homologous protein at the early treatment stage, followed by death receptor-5 upregulation, caspase activation, and β-actin/tubulin degradation. Cell cycle related protein cdc25C and mitotic regulator Aurora A kinase were inactivated by phenylacetylamide treatment, leading to an increase in the ratio inactive/active cdc2 kinase. As a result, phosphorylation of CDK substrates was decreased, and the MM cell mitotic division was largely blocked by treatment. Importantly, phenylacetylamide could overcome the chemoresistance of MM cells against dexamethasone or melphalan. Thus, targeting CB2 may represent an attractive approach to treat cancers of immune origin.

Original languageEnglish (US)
Pages (from-to)1796-1806
Number of pages11
JournalMolecular Carcinogenesis
Volume54
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Cannabinoid Receptors
Cytoskeleton
Multiple Myeloma
rimonabant
Transcription Factor CHOP
Aurora Kinase A
TNF-Related Apoptosis-Inducing Ligand Receptors
Cannabinoid Receptor Agonists
Cell Cycle Proteins
Melphalan
Gene Silencing
Tubulin
Caspases
Plasma Cells
Cell Division
Dexamethasone
Inhibitory Concentration 50
Actins
Immune System
Neoplasms

Keywords

  • Apoptosis
  • Cannabinoid receptor-2
  • Cell cycle
  • Cytoskeleton
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. / Feng, Rentian; Tong, Qin; Xie, Zhaojun; Cheng, Haizi; Wang, Lirong; Lentzsch, Suzanne; Roodman, G. David; Xie, Xiang Qun.

In: Molecular Carcinogenesis, Vol. 54, No. 12, 01.12.2015, p. 1796-1806.

Research output: Contribution to journalArticle

Feng, Rentian ; Tong, Qin ; Xie, Zhaojun ; Cheng, Haizi ; Wang, Lirong ; Lentzsch, Suzanne ; Roodman, G. David ; Xie, Xiang Qun. / Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. In: Molecular Carcinogenesis. 2015 ; Vol. 54, No. 12. pp. 1796-1806.
@article{28a74d66da2f4920988e6f0c4a0abed6,
title = "Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption",
abstract = "Cannabinoid receptor-2 (CB2) is expressed dominantly in the immune system, especially on plasma cells. Cannabinergic ligands with CB2 selectivity emerge as a class of promising agents to treat CB2-expressing malignancies without psychotropic concerns. In this study, we found that CB2 but not CB1 was highly expressed in human multiple myeloma (MM) and primary CD138+ cells. A novel inverse agonist of CB2, phenylacetylamide but not CB1 inverse agonist SR141716, inhibited the proliferation of human MM cells (IC50: 0.62∼2.5μM) mediated by apoptosis induction, but exhibited minor cytotoxic effects on human normal mononuclear cells. CB2 gene silencing or pharmacological antagonism markedly attenuated phenylacetylamide's anti-MM effects. Phenylacetylamide triggered the expression of C/EBP homologous protein at the early treatment stage, followed by death receptor-5 upregulation, caspase activation, and β-actin/tubulin degradation. Cell cycle related protein cdc25C and mitotic regulator Aurora A kinase were inactivated by phenylacetylamide treatment, leading to an increase in the ratio inactive/active cdc2 kinase. As a result, phosphorylation of CDK substrates was decreased, and the MM cell mitotic division was largely blocked by treatment. Importantly, phenylacetylamide could overcome the chemoresistance of MM cells against dexamethasone or melphalan. Thus, targeting CB2 may represent an attractive approach to treat cancers of immune origin.",
keywords = "Apoptosis, Cannabinoid receptor-2, Cell cycle, Cytoskeleton, Multiple myeloma",
author = "Rentian Feng and Qin Tong and Zhaojun Xie and Haizi Cheng and Lirong Wang and Suzanne Lentzsch and Roodman, {G. David} and Xie, {Xiang Qun}",
year = "2015",
month = "12",
day = "1",
doi = "10.1002/mc.22251",
language = "English (US)",
volume = "54",
pages = "1796--1806",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption

AU - Feng, Rentian

AU - Tong, Qin

AU - Xie, Zhaojun

AU - Cheng, Haizi

AU - Wang, Lirong

AU - Lentzsch, Suzanne

AU - Roodman, G. David

AU - Xie, Xiang Qun

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Cannabinoid receptor-2 (CB2) is expressed dominantly in the immune system, especially on plasma cells. Cannabinergic ligands with CB2 selectivity emerge as a class of promising agents to treat CB2-expressing malignancies without psychotropic concerns. In this study, we found that CB2 but not CB1 was highly expressed in human multiple myeloma (MM) and primary CD138+ cells. A novel inverse agonist of CB2, phenylacetylamide but not CB1 inverse agonist SR141716, inhibited the proliferation of human MM cells (IC50: 0.62∼2.5μM) mediated by apoptosis induction, but exhibited minor cytotoxic effects on human normal mononuclear cells. CB2 gene silencing or pharmacological antagonism markedly attenuated phenylacetylamide's anti-MM effects. Phenylacetylamide triggered the expression of C/EBP homologous protein at the early treatment stage, followed by death receptor-5 upregulation, caspase activation, and β-actin/tubulin degradation. Cell cycle related protein cdc25C and mitotic regulator Aurora A kinase were inactivated by phenylacetylamide treatment, leading to an increase in the ratio inactive/active cdc2 kinase. As a result, phosphorylation of CDK substrates was decreased, and the MM cell mitotic division was largely blocked by treatment. Importantly, phenylacetylamide could overcome the chemoresistance of MM cells against dexamethasone or melphalan. Thus, targeting CB2 may represent an attractive approach to treat cancers of immune origin.

AB - Cannabinoid receptor-2 (CB2) is expressed dominantly in the immune system, especially on plasma cells. Cannabinergic ligands with CB2 selectivity emerge as a class of promising agents to treat CB2-expressing malignancies without psychotropic concerns. In this study, we found that CB2 but not CB1 was highly expressed in human multiple myeloma (MM) and primary CD138+ cells. A novel inverse agonist of CB2, phenylacetylamide but not CB1 inverse agonist SR141716, inhibited the proliferation of human MM cells (IC50: 0.62∼2.5μM) mediated by apoptosis induction, but exhibited minor cytotoxic effects on human normal mononuclear cells. CB2 gene silencing or pharmacological antagonism markedly attenuated phenylacetylamide's anti-MM effects. Phenylacetylamide triggered the expression of C/EBP homologous protein at the early treatment stage, followed by death receptor-5 upregulation, caspase activation, and β-actin/tubulin degradation. Cell cycle related protein cdc25C and mitotic regulator Aurora A kinase were inactivated by phenylacetylamide treatment, leading to an increase in the ratio inactive/active cdc2 kinase. As a result, phosphorylation of CDK substrates was decreased, and the MM cell mitotic division was largely blocked by treatment. Importantly, phenylacetylamide could overcome the chemoresistance of MM cells against dexamethasone or melphalan. Thus, targeting CB2 may represent an attractive approach to treat cancers of immune origin.

KW - Apoptosis

KW - Cannabinoid receptor-2

KW - Cell cycle

KW - Cytoskeleton

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84945444575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945444575&partnerID=8YFLogxK

U2 - 10.1002/mc.22251

DO - 10.1002/mc.22251

M3 - Article

VL - 54

SP - 1796

EP - 1806

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 12

ER -